Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- IGF1 IGFA1 IGF-I IGFI MGF IGF1Ea IGF1Eb IGF1Ec IGF1R IGF2 IGF2R Met Escherichia
- Product Overview:
Insulin-like growth factor-1 (IGF-1) is a polypeptide hormone that regulates cell growth, maturation, and proliferation.{63328} It shares sequence homology with insulin and is composed of an N-terminal signal peptide, B-, C-, A-, and D-regions, and a C-terminal extension (E) peptide. Alternative splicing of the IGF1 pre-mRNA generates three isoforms, IGF-1Ea, IGF-1Eb, and IGF-1Ec, which have variable E peptides that are post-transcriptionally cleaved to produce the mature peptide. IGF-1 synthesis is induced by growth hormone (GH) and occurs primarily in the liver, where it is transported in the serum to other tissues via IGF binding proteins (IGFBPs), but it is also produced by a variety of other tissues, including the bone, where it acts in a paracrine or autocrine manner.{63329} IGF-1 binds the IGF-1 receptor (IGF-1R) with higher affinity than the IGF-2 receptor (IGF-2R) or insulin receptor (IR), inducing activation of a variety of signaling pathways, including PI3K/Akt and RAS/MAPK pathways, that stimulate cell proliferation and protect against apoptosis.{63330} IGF1 SNPs have been associated with increased risk of breast cancer, and serum IGF-1 levels are decreased in children with malnutrition.{63330,63331} Cayman’s IGF-1 (human, recombinant) protein can be used for binding assay and cell-based assay applications. The protein was synthesized from a DNA sequence encoding the mature form of human IGF-1 (Gly49-Ala118) with an N-terminal translation-initiating methionine (Met1). The expressed protein consists of 71 amino acids, has a calculated molecular weight of 7.8 kDa, and a predicted N-terminus of Met1.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.